← Leaderboards
Andrea Gambotto
University Of Pittsburgh At Pittsburgh
$6,859,177
Attributed
$10,754,242
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,754,242 · 12
By mechanism
U01$4,764,850 · 2
R01$1,753,967 · 2
R21$1,669,304 · 4
UM1$1,225,641 · 1
P01$504,458 · 1
P30$451,022 · 1
Top collaborators
- Danuta B Kozbor2 shared
- Kunle O Odunsi2 shared
- Grace M. Aldrovandi1 shared
- Cristian Apetrei1 shared
- Louis D Falo1 shared
- Charles R Rinaldo1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Karen A Norris$27,323,771
- Adrian E Morelli$11,040,013
- William J Federspiel$6,437,639
- Stephen H Thorne$3,784,781
- Kristin Leigh Depeaux$91,556
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseVectorVirusAdenovirusesViralImmunogenicityImmune ResponseResponseVaccinesDesignImmunityCellsIn VivoAdenovirus VectorRecombinantsTumorT-LymphocyteImmunizationNamesDoseServicesProteinsAntigensNeutralizing Antibody
Grant awards (26)
Microneedle patch delivery of replication-inducible monkeypox vaccine$547,988
R01 · FY2025 · AI · contact PI
Clinical evaluation of SARS-CoV-2 subunit vaccine in a Phase I human clinical study$1,225,641
UM1 · FY2020 · AI
U01 Proposal Transfer - 2021$3,250,758
U01 · FY2019 · CA
Reprograming the tumor microenvironment to overcome multiple primary and acquired immune resistance mechanisms in ovarian cancer$802,002
U01 · FY2019 · CA
Pre-clinical evaluation of a Zika virus vaccine$232,490
R21 · FY2018 · AI · contact PI
Pre-clinical evaluation of a Zika virus vaccine$193,332
R21 · FY2017 · AI · contact PI
Pre-clinical evaluation of an adenoviral-based MERS-CoV vaccine$203,040
R21 · FY2016 · AI · contact PI
Clinical manufacturing and toxicology testing of an adenoviral-based RSV vaccine$385,000
R56 · FY2015 · AI · contact PI
Pre-clinical evaluation of an adenoviral-based MERS-CoV vaccine$178,589
R21 · FY2015 · AI · contact PI
VECTOR CORE FACILITY$76,861
P30 · FY2014 · CA · contact PI
VECTOR CORE FACILITY$116,335
P30 · FY2013 · CA · contact PI
VECTOR CORE FACILITY$135,392
P30 · FY2012 · CA · contact PI
Adenoviral-based vaccine platform to overcome neutralizing immunity$224,978
R21 · FY2011 · AI · contact PI
VECTOR CORE FACILITY$61,177
P30 · FY2011 · CA · contact PI
Adenoviral-based vaccine platform to overcome neutralizing immunity$189,375
R21 · FY2010 · AI · contact PI
VECTOR CORE FACILITY$61,257
P30 · FY2010 · CA · contact PI
VECTOR CORE$95,395
P01 · FY2009 · CA · contact PI
VECTOR CORE$102,907
P01 · FY2008 · CA · contact PI
A Preventative Adenoviral-Based H5N1 Influenza Vaccine$243,601
R01 · FY2007 · AI · contact PI
VECTOR CORE$100,536
P01 · FY2007 · CA · contact PI
A Preventative Adenoviral-Based H5N1 Influenza Vaccine$962,378
R01 · FY2006 · AI · contact PI
VECTOR CORE$104,330
P01 · FY2006 · CA · contact PI
Preclinical Vector Core$712,090
U01 · FY2005 · HL
VECTOR CORE$101,290
P01 · FY2005 · CA
Uncoventional vectors for codon-optimized HIV antigens$223,375
R21 · FY2003 · AI
Uncoventional vectors for codon-optimized HIV antigens$224,125
R21 · FY2002 · AI